Is it now time to prepare psychiatry for a psychedelic future?
David Nutt, Ilana Crome, Allan H Young
The British Journal of Psychiatry May 20, 2024 DOI: 10.1192/bjp.2024.76 via OpenAlex
Summary
AI-generated from the abstractAustralia has reclassified psilocybin and MDMA from prohibited substances to prescription medicines for treatment-resistant depression and post-traumatic stress disorder, respectively. The feature examines the rationale behind these regulatory changes, the potential benefits and difficulties they present to psychiatric practice, and how mental health professionals and healthcare systems can adapt to integrate these treatments.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression MDMA Psilocybin PTSD |
| Keywords | Psychedelics Mental healthcare |
| Citations | 18 |
| Key finding | Australia's rescheduling of psilocybin and MDMA creates both opportunities and challenges for psychiatry communities and health systems in responding to these developments. |
Abstract
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.